Key result
Phase III trials demonstrate that new oral anticoagulants are non-inferior to standard therapy for preventing recurrent venous thromboembolism, with generally lower or comparable rates of bleeding.
Why the study?
Do new oral anticoagulants (NOACs) provide non-inferior efficacy and improved safety compared to traditional heparin and vitamin K antagonists for the acute treatment and secondary prevention of VTE?
Do new oral anticoagulants (NOACs) provide non-inferior efficacy and improved safety compared to traditional heparin and vitamin K antagonists for the acute treatment and secondary prevention of VTE?
Answers are grounded in this paper and cite their sources.
This review highlights that NOACs offer a non-inferior, more convenient alternative to traditional heparin/VKA therapy for VTE management, with comparable or superior safety profiles regarding bleeding risk.
The traditional treatment of venous thromboembolism (VTE) has been use of heparin and vitamin K antagonists (VKA), and although shown to be effective, they have numerous limitations. New oral anticoagulants (NOACs) including direct thrombin (factor IIa) inhibitors (dabigatran) and selective factor Xa inhibitors (rivaroxaban, apixaban and edoxaban) have emerged as promising alternatives with the potential to overcome the limitations of traditional treatments. Clinical trials have been performed with a view to making significant changes to the acute, long-term and extended treatment of VTE. Data are now available on the efficacy and safety, including bleeding rates, of the NOACs in comparison with VKA in the acute treatment and secondary prevention of VTE as well as in comparison with placebo extended VTE treatment. This review compares and contrasts the design and results of the Phase III trials of NOACs in VTE and discusses the implications of the NOACs in terms of treatment strategies in VTE patients.
No takes yet. Share an insight, caveat, or question.
Cohen et al. (2014) conducted a review in Venous thromboembolism (VTE). New oral anticoagulants (NOACs) vs. Vitamin K antagonists (VKA) or placebo was evaluated. Phase III trials demonstrate that new oral anticoagulants are non-inferior to standard therapy for preventing recurrent venous thromboembolism, with generally lower or comparable rates of bleeding.
Synapse has enriched 10 related papers. Consider them for comparative context: